Representing China's Precision Medicine Players, Genetron Health Delivered Speeches at 2019 Cancer Precision Medicine, China Oncology Conference

Release time:2019-08-18

On August 16-19, 2019, the 2019 China Oncology Conference (CCO) sponsored by China Anti-Cancer Association was held in Chongqing, with nearly 40 academicians, 2,000 well-known scholars and experts in oncology, and more than 30,000 elites of the oncology community gathered in this largest academic conference, with the highest specifications and the widest coverage in the field of oncology in China.


Representing China's Precision Medicine Players, Genetron Health Delivered Speeches at 2019 Cancer Precision Medicine, China Oncology Conference


Genetron Health was invited to attend the 4th International Cancer Precision Medicine Summit to showcase the strength of some China's scientific researches, technological innovation and the great potential of commercialization.


Mr. Sizhen Wang, co-founder and CEO of Genetron Health, and Professor Yuchen Jiao, Chief Technology Officer of Genetron Health, were invited to hold roundtable discussions and keynote speeches. The forum also brought together a number of masters and gurus in this field, including Professor Webster K. Cavenee, academician of the American Academy of Sciences, German Academy of Sciences and Chinese Academy of Engineering, Professor Raju Kucherlapati, academician of the American College of Medicine, Professor Hao Xishan, academician of the Chinese Academy of Engineering, Professor Qimin Zhan, academician of the Chinese Academy of Engineering, and Professor Ruihua Xu, Dean of the Cancer Prevention Center of Sun Yat-sen University, and other famous experts and scholars.


Representing China's Precision Medicine Players, Genetron Health Delivered Speeches at 2019 Cancer Precision Medicine, China Oncology Conference


Academicians of the world making insightful speeches


Precision medicine has become the direction of medical development in all countries of the world. In this roundtable discussion on the trend of precision medicine, Mr. Wang said: “Cancer has become a field of huge potential for precision medicine. Genetron Health has worked on it for many years and has gradually become the top in tumor precision medicine in China.Although there is still some controversy in terms of commercialization of innovative technologies represented by genetic testing, it still cannot stop the trend of commercialization. Because the market demand and technical advantages cannot be ignored, and the change of mindset is only a matter of time. Each industry is inevitably shocked by growing pains. Luckily, technology and products in this industry are developing rapidly, and the industry is increasingly maturing. I believe that the future of precision medicine is bright.'


Representing China's Precision Medicine Players, Genetron Health Delivered Speeches at 2019 Cancer Precision Medicine, China Oncology Conference


Mr. Sizhen Wang, Co-founder and CEO of Genetron Health


'As the theme of this conference - cancer prevention and treatment states, Genetron Health is committed to the full cycle cancer care from early screening, diagnosis, therapeutic decision, to prognosis monitoring, and provides a variety of services and products. Among them, prevention and early screening of cancer will be an important direction for cancer precision medicine. In March this year, Genetron Health publishes an important research result in Proceedings of the National Academy of Sciences journal on early screening of liver cancer in cooperation with the Cancer Hospital of Chinese Academy of Medical Sciences, which is an important technological breakthrough in the field.' Sizhen Wang said.


Speaking of early screening of cancer, Professor Yuchen Jiao, Chief Technology Officer of Genetron Health, said in his keynote speech: 'Liver cancer is a high-incidence cancer in China, and the number of Chinese patients is about half of that in the world. After a long period of in-depth exploration, based on genomics research, we have invented “Genetron Mutation Capsule Technology, a liquid biopsy technology with high sensitivity and specificity, in combination with protein marker detection, is performing well in the detection of prospective cohort of hepatitis B virus carriers.


331 alpha-fetoprotein and ultrasonic B-normal hepatitis B virus carriers were screened: 24 positive samples were detected, and 4 cases of liver cancer (early-stage liver cancer less than 3 cm) were found during follow-up visits at 6-8 months. A better prognosis may be obtained by surgical resection due to the early detection; no trace of liver cancer occurred in the follow-up of the remaining 307 negative samples during the same follow-up period.'


Representing China's Precision Medicine Players, Genetron Health Delivered Speeches at 2019 Cancer Precision Medicine, China Oncology Conference


Professor Yuchen Jiao, Chief Technology Officer of Genetron Health


Regarding the core technology of Genetron Mutation Capsule, Professor Yuchen Jiao also said: 'This technology can achieve accurate detection of common mutations in liver cancer such as cfDNA point mutation, insertion and deletion mutation, HBV virus integration, the sample size needed is extremely small, and the sample can be reused many times. The research method has been further optimized, in addition to the biomarkers reported in the article, we can also detect a variety of other gene variants such as methylation, etc. The optimized technology is now validated in more samples from multiple centers, and can also be used in other cancers.'


Representing China's Precision Medicine Players, Genetron Health Delivered Speeches at 2019 Cancer Precision Medicine, China Oncology Conference


From Left to Right:


Mr. Sizhen Wang, Co-founder and CEO of Genetron Health;


Mr. Han Li, Marketing Director of Siemens Diagnosis (China);


Mr. Tom Miller, CEO of Greybird Investment, USA;


Ms. Wen Mao, World Economic Forum (Davos) , Head of Precision Medicine Project


During the conference, many guests mentioned that the breakthroughs in basic research and technological innovation were gratifying, but their clinical transformation was more important. How to carry out the clinical application and commercialization of innovation results and improve the accessibility of products and technologies to benefit more patients is a topic that needs to be discussed in depth. In this regard, Mr. Sizhen Wang, co-founder and CEO of Genetron Health, pointed out: 'In the future, transformation ability may be another important criterion for measuring the strength of enterprises.


Genetron Health always adheres to the research philosophy of 'Exploration, discovery, application and change'. With the close cooperation of experienced research teams, technical teams and marketing teams, we are striving to accelerate the clinical transformation and commercialization of basic research results, taking into account the reliability and accessibility of technology and products, and endeavor to provide more advanced, reliable and practical services for more users, so that precision medicine can be implemented and benefit the public.


The pictures in the article are from CCO organizer. The copyright belongs to the original author. 


COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
Genetron Health Genetron Health Management
COPYRIGHT © 2020-2023泛生子. ALL RIGHTS RESERVED
犀牛云提供云计算服务
Messages
  • *To
  • *Subject
  • *Name
  • *Tel
  • Work Unit
  • *Email
  • 详细说明:
  • Verification code:
Genetron Health Genetron Health Management